Show simple item record

dc.contributor.authorFagotti, Juliane
dc.contributor.authorTarga, Adriano D S
dc.contributor.authorRodrigues, Lais S
dc.contributor.authorNoseda, Ana Carolina D
dc.contributor.authorDorieux, Flávia W C
dc.contributor.authorScarante, Franciele F
dc.contributor.authorIlkiw, Jessica L
dc.contributor.authorLouzada, Fernando M
dc.contributor.authorChowdhury, Namrata R
dc.contributor.authorvan der Veen, Daan R
dc.contributor.authorMiddleton, Benita
dc.contributor.authorPennings, Jeroen L A
dc.contributor.authorSwann, Jonathan R
dc.contributor.authorSkene, Debra J
dc.contributor.authorLima, Marcelo M S
dc.date.accessioned2019-03-22T12:49:46Z
dc.date.available2019-03-22T12:49:46Z
dc.date.issued2019-02-13
dc.identifier.issn2045-2322
dc.identifier.pmid30760786
dc.identifier.doi10.1038/s41598-018-37657-6
dc.identifier.urihttp://hdl.handle.net/10029/622947
dc.description.abstractParkinson's disease (PD) is a chronic disorder that presents a range of premotor signs, such as sleep disturbances and cognitive decline, which are key non-motor features of the disease. Increasing evidence of a possible association between sleep disruption and the neurodegenerative process suggests that sleep impairment could produce a detectable metabolic signature on the disease. In order to integrate neurocognitive and metabolic parameters, we performed untargeted and targeted metabolic profiling of the rotenone PD model in a chronic sleep restriction (SR) (6 h/day for 21 days) condition. We found that SR combined with PD altered several behavioural (reversal of locomotor activity impairment; cognitive impairment; delay of rest-activity rhythm) and metabolic parameters (branched-chain amino acids, tryptophan pathway, phenylalanine, and lipoproteins, pointing to mitochondrial impairment). If combined, our results bring a plethora of parameters that represents reliable early-phase PD biomarkers which can easily be measured and could be translated to human studies.en_US
dc.language.isoenen_US
dc.titleChronic sleep restriction in the rotenone Parkinson's disease model in rats reveals peripheral early-phase biomarkers.en_US
dc.typeArticleen_US
dc.identifier.journalSci Rep 2019; 9(1):1898en_US
dc.source.journaltitleScientific reports


This item appears in the following Collection(s)

Show simple item record